MicrobiomeTrials
  • Search Trials
  • Conditions
  • Learn
  • About
Data source: ClinicalTrials.gov
This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Sign up for updates
Home/Conditions/Ulcerative Colitis
Condition Guide

Ulcerative Colitis

From chronic flares to lasting remission

Ulcerative colitis (UC) causes inflammation and ulcers in the colon lining, leading to painful flares. Of all IBD conditions, UC has seen some of the most exciting microbiome trial results — with FMT achieving remission in multiple studies.

View Recruiting Trials

The Microbiome Connection

How Ulcerative Colitis relates to gut health

Common Symptoms

  • Bloody diarrhea
  • Urgent need to defecate
  • Abdominal cramping
  • Weight loss
  • Fatigue
  • Inability to defecate despite urgency

How the Microbiome is Involved

UC is closely linked to an overgrowth of harmful bacteria and a loss of commensal species that regulate immune tolerance in the colon. Short-chain fatty acids like butyrate — produced by healthy gut bacteria — are depleted in UC, leaving the colon lining vulnerable and inflamed. Microbiome therapies aim to directly address this deficit.

Active Trials

View all 271 trials
AIM-IBD: A Microbiome-Targeted Supplement in Mild-to-Moderate Ulcerative ColitisRecruiting
Ulcerative Colitis (UC)Inflammatory Bowel Disease (IBD)Colitis
This Phase 2b randomized, double-blind, placebo-controlled, multicenter trial will evaluate the efficacy and safety of a…
Izmir, Turkey (Türkiye)Est. completion May 30, 2027
View Trial →
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative ColitisPhase 2Recruiting
Ulcerative ColitisInflammatory Bowel DiseasesColitisColitis, Ulcerative
This is a Phase 2, multicenter, proof-of-concept platform study in adult participants with moderately to severely active…
Canoga Park, United StatesEst. completion Jun 2026
View Trial →
A Study to Evaluate the Activity, and Safety of Vixarelimab in Participants With Moderate to Severe Active Ulcerative ColitisPhase 1Recruiting
Moderate to Severe Ulcerative Colitis
This study aims to evaluate the pharmacodynamic (PD) effects of vixarelimab in the gut of participants with active moder…
Berlin, GermanyEst. completion Jul 9, 2026
View Trial →

Related Conditions

Inflammatory Bowel Disease (IBD)
Restoring balance to a disrupted gut
Explore
Crohn's Disease
Tackling one of the gut's toughest conditions
Explore
C. difficile (C. diff)
The condition where microbiome therapy works best
Explore

Get notified about new Ulcerative Colitis trials

We’ll email you when new recruiting trials for your condition are posted. No spam, ever.